The global epinephrine auto-injectors market is estimated to experience healthy growth during the forecast period. In the past few years, drug delivery has become a significant factor in improving the quality of life. Syringes and injectors have evolved substantially to cater to changing clinical and patient demands. The appearance and easy usability of disposable drug injectors have created opportunities for auto-injector drug manufacturers as they offer many advantages over traditional methods.
Epinephrine (Adrenaline) auto-injectors are the latest trend in the market and are used to treat anaphylaxis, which occurs in people suffering from cardiac arrest, allergy, and asthma. Epinephrine is a colorless clear sterile solution also called adrenaline. These auto-injectors are the basic treatment for treating anaphylaxis which enables non-medical people to treat the disorder effectively. Delayed administration may increase the risk of death. The drug enables to reverse symptoms of an allergic reaction by opening airways, accelerating the heart rate, and maintaining blood pressure. They are available as pre-filled auto injecting devices that contain the drug to be injected under the skin or into the muscle along the outer side of the thigh. Currently, there are two Epinephrine auto-injectors available Anapen and Epipen, and they are classified as S3 drugs that allow them to be bought from a pharmacy without a prescription. Anapen has a considerably longer shelf life as compared to Epipen.
Administering an injection by a non-medical person poses risks and challenges. The use of an auto-injector can benefit the healthcare professional and user in many ways such as reduced anxiety, ease in self-administering the drug, improved safety, etc. In addition, auto-injectors offer business benefits such as meeting customer needs, meeting legislative requirements, etc.
The global epinephrine auto-injector market has been growing rapidly. One major driver for this market growth has been the increasing ubiquity of allergies amongst people. Therefore, the increase in the number of patients allergic to dust, insect bites and venom, food and food additives, has driven the market growth. Furthermore, investments by vendors in Research & Development activities to develop Chlorofluorocarbon-free epinephrine auto-injector inhalers using hydrofluoroalkanes propellant instead have also accelerated the market growth. Adverse side effects such as cardiac arrhythmia, pulmonary edema, vomiting, cerebral hemorrhage, etc. as a result of excessive epinephrine usage can pose to be a challenge to the market.
The key participants in this epinephrine auto-injectors market include Amedra Pharmaceuticals LLC, Mylan Inc, ALK Abello, Sanofi SA, and Lincoln Medical Ltd. Other vendors include Itelliject Inc, Adamis Pharmaceuticals Corp, Hospira Inc, Teva Pharmaceuticals Ltd and Antares Pharma Inc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.